Researchers reported first clinical experience with a high-avidity BCMA-directed CAR T-cell product (MDC-CAR-BCMA001) in relapsed or refractory systemic light chain amyloidosis. In a seven-patient cohort receiving 800 million CAR T cells after conditioning lymphodepletion, investigators observed an overall response rate of 86%, including three complete remissions with negative measurable residual disease. The therapy also produced organ responses across cardiac, renal, and neurologic manifestations including polyneuropathy and myopathy, with cytokine release syndrome occurring in all patients but reported as grade 2 or lower in most cases and manageable with standard interventions such as tocilizumab and dexamethasone. Because no commercial BCMA CAR T products are approved in Europe for this indication, the dataset provides an early efficacy-and-tolerability signal that may inform subsequent study design and comparative positioning versus other plasma-cell–targeted strategies.
Get the Daily Brief